2 research outputs found
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠ»ΡΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡΠ° Π½Π° ΡΠΎΠ½Π΅ Π‘OVID-19, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ ΡΠ°ΠΊΡΠΈΠΊΠ° Π»Π΅ΡΠ΅Π½ΠΈΡ
In a review article based on my own clinical experience of managing patients with acute myocardial injury and fulminant myocarditis, taking into account expert recommendations on the clinical treatment of myocardial damage associated with novel coronavirus infection a National clinical geriatric medical research center, division of cardiovascular diseases, the Chinese geriatrics society, Department of cardiology, Beijing Medical Association and European clinics discusses the pathogenesis, diagnosis and treatment of myocardial damage and FM patients, infected with SARS-CoV-2 in the context of the COVID-19 pandemic. Clinical features and diagnostic criteria are presented, including screening tests of markers of myocardial damage in the form of a highly sensitive troponin test, a natriuretic peptide. The article discusses in detail the pathogenesis and mechanisms of myocardial damage, including immune mechanisms, cytokine storm, systemic inflammation with macro- and microvascular dysfunction and the development of myocardial dysfunction with acute heart failure, hypotension, cardiogenic shock and/or life-threatening heart rhythm disorders caused by hypoxia and metabolic disorders at the cellular level. Features of the clinical course of fulminant myocarditis in infected patients (SARS-CoV-2) in the conditions of the COVID-19 pandemic are presented. For the first time, a detailed histo-morphological analysis of pathological myocardial injuries and complications is presented on the basis of unique autopsy material on post-mortem diagnostics of various pathoanatomic autopsies of those who died from COVID-19 in Moscow. Based on the clinical, functional and morphological material, the Protocol of etiopathogenetic treatment is presented. The basis of standard therapy is considered antiviral drugs, immunoglobulin G, the use of monoclonal antibodies to interleukin-6, anticoagulants, glucocorticoids, depending on the clinical situation, cardioprotectors and symptomatic treatment are recommended to maintain the heart, which in combination can achieve a certain clinical effectiveness. As adjuvant cardioprotective targeted therapy, the sodium salt of phosphocreatine is considered in order to preserve the myocardium, maintain its contractility and vital activity.Π ΠΎΠ±Π·ΠΎΡΠ½ΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΡΡΠ»ΡΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
SARS-CoV-2, Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ COVID-19. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΠ΅ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ΠΎΠ²ΡΠ΅ ΡΠ΅ΡΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Π² Π²ΠΈΠ΄Π΅ Π²ΡΡΠΎΠΊΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠΏΠΎΠ½ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠ°, Π½Π°ΡΡΠΈΠΉΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄Π°. ΠΠ΅ΡΠ°Π»ΡΠ½ΠΎ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΠ΅ ΠΈΠΌΠΌΡΠ½Π½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ, ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΡΠΉ ΡΡΠΎΡΠΌ, ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ Ρ ΠΌΠ°ΠΊΡΠΎ- ΠΈ ΠΌΠΈΠΊΡΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Ρ ΠΎΡΡΡΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ, Π³ΠΈΠΏΠΎΡΠ΅Π½Π·ΠΈΠ΅ΠΉ, ΠΊΠ°ΡΠ΄ΠΈΠΎΠ³Π΅Π½Π½ΡΠΌ ΡΠΎΠΊΠΎΠΌ ΠΈ/ΠΈΠ»ΠΈ ΠΆΠΈΠ·Π½Π΅ΡΠ³ΡΠΎΠΆΠ°ΡΡΠΈΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ°, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΠ΅ Π³ΠΈΠΏΠΎΠΊΡΠΈΠ΅ΠΉ ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ Π½Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΡΠΎΠ²Π½Π΅. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠ»ΡΠΌΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
SARS-CoV-2, Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ COVID-19. ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ Π³ΠΈΡΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠ½ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°ΡΡΠΎΠΏΡΠΈΠΉΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΏΠΎ ΠΏΠΎΡΠΌΠ΅ΡΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΡΠΊΡΡΡΠΈΠΉ ΡΠΌΠ΅ΡΡΠΈΡ
ΠΎΡ COVID-19 Π² ΠΠΎΡΠΊΠ²Π΅. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΏΡΠΎΡΠΎΠΊΠΎΠ» ΡΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΡΠΈΡΡΠ°ΡΠΈΠΈ Π΄Π»Ρ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠ°Π±ΠΎΡΡ ΡΠ΅ΡΠ΄ΡΠ° Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ°ΡΠ³Π΅ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ Π½Π°ΡΡΠΈΠ΅Π²Π°Ρ ΡΠΎΠ»Ρ ΡΠΎΡΡΠΎΠΊΡΠ΅Π°ΡΠΈΠ½Π° Ρ ΡΠ΅Π»ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠΎΠΊΡΠ°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΈ ΠΆΠΈΠ·Π½Π΅Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°. ΠΠ»Ρ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ COVID-19, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΎΡΡΡΠΎΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, ΡΡΠ»ΡΠΌΠΈΠ½Π°Π½ΡΠ½ΡΠΉ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΡ, Π² ΠΏΡΠΎΡΠΎΠΊΠΎΠ» Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ΠΎ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΊΠΎΡΠΎΡΠ°Ρ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΡΡΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
Features of the cell composition of inflammatory infiltrate in different phases of diffuse alveolar lung damage with COVID-19
Background. Acute respiratory distress syndrome (ARDS) with COVID-19 has a worse prognosis than ARDS with other diseases. Mortality from ARDS with COVID-19 is 26.0 β 61.5%, and due to other causes β 35.3β37.2%. Objective. To find of the correlation between polymorphonuclear leukocytes (PMNs), lymphocytes, and macrophages in the cellular composition of the inflammatory infiltrate at different stages and phases of diffuse alveolar damage (DAD) with COVID-19, analyzing the autopsy material. Material and methods. The lung tissue of 25 patients who died from ARDS with COVID-19 without a secondary bacterial or mycotic infection, another thanatologically significant pathology of the lungs, was studied. To study the cellular composition of the inflammatory infiltrate and the dynamics of its changes a double immunohistochemical analysis of the expression of antibodies to CD15, CD3, and CD68 was used. Results. The inflammatory infiltrate and intraalveolar exudate in the exudative phase of DAD was represented by 56.8% of PMNs (CD15-positive cells; hereinafter β the average value of the percentage of positive cells to the total number of cells of the inflammatory infiltrate), 6.9% β lymphocytes (CD3-positive cells) and 19.5% macrophages (CD68-positive cells). In the early stage of the proliferative phase: 14.1% PMNs, 38.7% lymphocytes and 13.5% macrophages. In the late stage of the proliferative phase: 11.3% PMNs, 14.5% lymphocytes and 39.3% macrophages. Conclusions. In the exudative phase of DAD a statistically significant predominance of PMN was revealed, which could determine the main volume of lung damage and the severity of ARDS with COVID-19. In the early stage of the proliferative phase of DAD, a statistically significant change in the composition of the inflammatory infiltrate was revealed to compare with the exudative phase: a significant decrease in the content of PMNs relative to the total number of cells in the inflammatory infiltrate; an increase in the number of lymphocytes, which is probably associated with the start of organization and repair processes. In the late stage of the proliferative phase of DAD, compared with its early stage, was revealed a statistically significant increase in the number of macrophages in ratio. Β© 2022, Media Sphera Publishing Group. All rights reserved